Skip to main content
Arch Biopartners Inc. logo

Arch Biopartners Inc. — Investor Relations & Filings

Ticker · ARCH ISIN · CA03938C1041 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 201 across all filing types
Latest filing 2026-04-13 Regulatory Filings
Country CA Canada
Listing TSXV ARCH

About Arch Biopartners Inc.

https://archbiopartners.com/

Arch Biopartners is a therapeutic biotechnology company focused on developing novel, mechanism-based drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The company's pipeline addresses major unmet needs by targeting underlying drivers of kidney damage. Lead drug candidates include LSALT peptide (Metablok™), a first-in-class DPEP1 inhibitor in Phase II trials for cardiac surgery-associated AKI (CS-AKI), and Cilastatin, a repurposed DPEP1 inhibitor in Phase II for drug toxin-related AKI. Additionally, Arch is advancing a pre-clinical CKD platform targeting the IL-32 cytokine, implicated in diabetic kidney disease (DKD), the leading cause of kidney failure globally. These programs position Arch to deliver first-in-class therapeutics across the spectrum of kidney diseases.

Recent filings

Filing Released Lang Actions
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 1% confidence The document is a Canadian securities regulatory form (Form 45-106F1 Report of Exempt Distribution) filed on SEDAR+. It details an exempt distribution of securities (dates, purchasers, amounts) under NI 45-106. It is not an annual or interim financial report, earnings release, proxy statement, dividend notice, or management presentation. It is a formal regulatory filing that does not fit into other specialized categories, making it a general regulatory filing (RNS).
2026-04-13 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a Canadian continuous disclosure filing (Form 51-102F3) notifying investors of a material change—the closing of a non-brokered private placement of common shares for gross proceeds of CAD 600,000. This is a direct update on the company’s fundraising and capital structure. This falls squarely under the “Capital/Financing Update” category, which covers announcements of fundraising activities through private placements.
2026-04-13 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the closing of a non-brokered private placement of common shares, detailing the number of shares issued, price, proceeds, related party transaction, hold period, and use of proceeds. This is an update on the company’s financing activity (fundraising and capital structure change) rather than the full report itself. It therefore fits the Capital/Financing Update category.
2026-04-02 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release detailing a non‐brokered private placement offering of 1,000,000 common shares to raise CAD 600,000 as general working capital. This is a fundraising/financing activity announcement, fitting the Capital/Financing Update category.
2026-03-30 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Audit Report / Information Classification · 1% confidence The document is a 'Form 52-109FV1', which is a Venture Issuer Basic Certificate used in Canadian securities regulation to certify annual filings. It is a standalone regulatory certification document signed by the CEO, confirming the accuracy of the annual financial statements and MD&A. Since it is a specific regulatory certification document rather than the annual report itself or a general announcement, it falls under the 'Regulatory Filings' category as it does not fit into the specific definitions of 10-K (which is a US-specific term) or other categories. FY 2025
2026-01-29 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Audit Report / Information Classification · 1% confidence The document is a 'Certification of Annual Filings' (Form 52-109FV1) for a venture issuer. This is a regulatory requirement accompanying annual financial filings to certify the accuracy of the financial statements and MD&A. Since it is a standalone regulatory certification document rather than the annual report itself, and it does not fit into specific categories like 'Annual Report' (10-K) or 'Management Reports' (MDA), it is classified as a Regulatory Filing. FY 2025
2026-01-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.